

1 **Title: Correlation of the commercial anti-SARS-CoV-2 receptor binding domain**
2 **antibody test with the chemiluminescent reduction neutralizing test and possible**
3 **detection of antibodies to emerging variants**

4

5

6 Yoshitomo Morinaga ^a, Hideki Tani ^{a, b}, Yasushi Terasaki ^c, Satoshi Nomura ^c, Hitoshi
7 Kawasuji ^d, Takahisa Shimada ^{a, b}, Emiko Igarashi ^b, Yumiko Saga ^{a, b}, Yoshihiro Yoshida ^a,
8 Rei Yasukochi ^d, Makito Kaneda ^d, Yushi Murai ^d, Akitoshi Ueno ^d, Yuki Miyajima ^d, Yasutaka
9 Fukui ^d, Kentaro Nagaoka ^d, Chikako Ono ^{e, f}, Yoshiharu Matsuura ^{e, f}, Takashi Fujimura ^c,
10 Yoichi Ishida ^c, Kazunori Oishi ^g, and Yoshihiro Yamamoto ^e

11

12 ^a Department of Microbiology, Toyama University Graduate School of Medicine and
13 Pharmaceutical Sciences, Toyama, Japan

14 ^b Department of Virology, Toyama Institute of Health, Toyama, Japan

15 ^c Toyama City Hospital, Toyama, Japan

16 ^d Department of Clinical Infectious Diseases, Toyama University Graduate School of
17 Medicine and Pharmaceutical Sciences, Toyama, Japan

18 ^e Laboratory of Virus Control, Center for Infectious Disease Education and Research
19 (CiDER), Osaka University, Osaka, Japan

20 ^f Laboratory of Virus Control, Research Institute for Microbial Diseases (RIMD), Osaka

21 University, Osaka, Japan

22 ^g Toyama Institute of Health, Toyama, Japan

23

24

25 **Corresponding author**

26 Yoshitomo Morinaga, MD, PhD

27 Department of Microbiology, Graduate School of Medicine and Pharmaceutical Sciences,

28 University of Toyama, 2630 Sugitani, Toyama, 930-0194 Japan

29 Phone: +81-76-434-7256

30 Fax: +81-76-434-5020

31 E-mail: morinaga@med.u-toyama.ac.jp

32

33 **Running title**

34 SARS-CoV-2 neutralization and antibody tests

35

36 **Key words**

37 neutralizing antibodies; seroconversion; receptor binding domain; convalescent; high

38 throughput

39

40

41 **List of abbreviations**

42 CRNT – Chemiluminescent reduction neutralizing test

43 RBD – Receptor binding domain

44 RT-qPCR – Quantitative reverse transcriptase–polymerase chain reaction

45 VSV – Vesicular stomatitis virus

46 DMEM – Dulbecco’s modified Eagle’s medium

47 FBS – Fetal bovine serum

48 COV – Cut-off value

49

50 **Abstract**

51

52 **Background**

53 Serological tests are beneficial for recognizing the immune response against
54 SARS-CoV-2. To identify protective immunity, optimization of the chemiluminescent
55 reduction neutralizing test (CRNT), using pseudotyped SARS-CoV-2, is critical. Whether
56 commercial antibody tests are comparably accurate is unknown.

57 **Methods**

58 Serum samples collected before variants were locally found were obtained from
59 confirmed COVID-19 patients (n = 74), confirmed non-COVID-19 individuals (n = 179), and
60 unscreened individuals (suspected healthy individuals, n = 229). The convalescent phase
61 was defined as the period after day 10 from disease onset. The CRNT against pseudotyped
62 viruses displaying the wild-type spike protein and a commercially available anti-receptor
63 binding domain (RBD) antibody test were assayed. The CRNT was also assayed, using
64 South African (SA) and United Kingdom (UK)-derived variants.

65 **Results**

66 The CRNT (cut off value, 50% inhibition) and the anti-RBD antibody test (cut off
67 value, 0.8 U/mL) concurred regarding symptomatic COVID-19 patients in the convalescent
68 phase and clearly differentiated between patients and suspected healthy individuals

69 (sensitivity; 95.8% and 100%, specificity; 99.1% and 100%, respectively). Anti-RBD
70 antibody test results correlated with neutralizing titer ($r = 0.47$, 95% CI 0.20-0.68).
71 Compared with the wild-type, CRNT reduction was observed for the SA and UK-derived
72 variants. Of the samples with ≥ 100 U/mL by the anti-RBD antibody test, 77.8% and 88.9%
73 showed $\geq 50\%$ neutralization against the UK and the SA variants, respectively.

74 **Conclusion**

75 The CRNT and commercial anti-RBD antibody test effectively classified
76 convalescent COVID-19 patients. The strong positive results using the commercial antibody
77 test can reflect neutralizing activity against emerging variants.

78

79

80 **Introduction**

81

82 Understanding the status of immunity acquisition against severe acute respiratory
83 syndrome coronavirus 2 (SARS-CoV-2) will help us overcome the difficulties related to the
84 coronavirus disease (COVID-19) pandemic. Serological tests can provide information on
85 the immune status after viral exposure and vaccination. The virus neutralizing test is a
86 method for directly determining the functional ability of the immune response; however, it is
87 not suitable as a routine test in clinical laboratories due to its complexity and the risks
88 associated with using live viruses.

89 We previously established the chemiluminescence reduction neutralization test
90 (CRNT) for the evaluation of immunity to SARS-CoV-2, using pseudotyped virus (1). The
91 CRNT can assess the inhibitory effect of serum samples on viral attachment and entry into
92 the target cells. As observed in our previous reports (1, 2), the inhibition of the infectivity of
93 sera from symptomatic COVID-19 patients gradually increased during the follow-up period,
94 suggesting that the CRNT reflects the status of immunity acquisition. Meanwhile,
95 commercial antibody tests that do not specify functional antibodies are becoming available.
96 Some tests can detect antibodies specific to the receptor-binding domain (RBD) of the
97 spike protein on SARS-CoV-2 that binds to the ACE2 receptor expressed on the targeted
98 cells (3-5). Therefore, any correlation between commercial test results and protective

99 function against SARS-CoV-2 is of epidemiological and clinical interest.

100 Several SARS-CoV-2 variants have been identified (6). The B.1.351 variant, which
101 was originally identified in South Africa, is characterized by amino acid mutations such as
102 K417N, E484K, and N501Y in the RBD of the spike protein (7). These mutations can be
103 related to the neutralizing function of the immune response of previous COVID-19 as well
104 as viral binding because of structural changes in the contact sites to the ACE2 receptor (8).
105 The B.1.1.7 variant that emerged in the United Kingdom also has the mutation N501Y (9)
106 which has been shown to increase the affinity to the ACE2 receptor (10). It has been
107 suggested that N501Y and the other mutations are not related to the reduction of
108 neutralization (11, 12); however, potentially reduced neutralization has also been implied
109 (13, 14). Thus, elucidating whether antibodies present in the sera from COVID-19 patients
110 have neutralizing activity against emerging SARS-CoV-2 variants remains paramount.

111 The optimization of immune response tests may help the accurate evaluation of
112 infection-induced antibodies as well as the efficacy of vaccination. The performance of the
113 CRNT to recognize individuals who have likely acquired immunity was evaluated. In
114 addition, we investigated whether the neutralizing effects were reasonably predictable by a
115 commercially available antibody test.

116

117

118 **Materials and Methods**

119 ***Collection of specimens***

120 Serum samples were collected from COVID-19 patients, uninfected close contacts,
121 and suspected healthy individuals at the Toyama University Hospital and Toyama City
122 Hospital. The sera were frozen at -80 °C until serological assays were performed. All
123 samples were collected before SARS-CoV-2 variants were found locally.

124 The diagnosis of COVID-19 was confirmed by the positive results of
125 nasopharyngeal swab samples on the SARS-CoV-2 quantitative reverse
126 transcriptase–polymerase chain reaction (RT-qPCR) testing (confirmed COVID-19 patients).
127 The uninfected close contacts, including health care workers, were those who were tested
128 at least once as negative on the SARS-CoV-2 RT-qPCR (confirmed non-COVID-19
129 individuals). The suspected healthy individuals (unscreened individuals) were health care
130 workers at the Toyama University Hospital, who were not tested via SARS-CoV-2 RT-qPCR,
131 as they were not considered at risk and did not present with symptoms nor reported close
132 contacts.

133 Basic clinical characteristics were obtained from medical records or questionnaires
134 from all participants who had undergone SARS-CoV-2 RT-qPCR. The obtained
135 characteristics included symptoms (fever, cough, sputum, sore throat, nasal discharge, loss
136 of taste, loss of smell, dyspnea, and others), underlying diseases (malignant diseases,

137 diabetes, immunosuppression, renal failure, liver failure, and systemic lupus
138 erythematosus), and medication (corticosteroids excluding ointment, immunosuppressants,
139 anti-tumor drugs, anti-rheumatoid drugs, and radiological therapy).

140 For suspected healthy individuals, medical information on symptoms, underlying
141 diseases, and medications was not collected. The serum samples from these individuals
142 were originally collected in July and August 2020 for the screening of subclinical
143 SARS-CoV-2 infections among staff by the infection control team because at least 3 months
144 had passed since the first case of COVID-19 was hospitalized.

145

146 ***Virological investigation***

147 SARS-CoV-2 RT-qPCR was performed at officially approved laboratories, including
148 the University of Toyama, Toyama Institute of Health, and external private laboratories. The
149 methods of SARS-CoV-2 RT-qPCR were dependent on each laboratory. Cases of
150 RNAemia were screened (15), and the results were used as the demographic background.
151 When the remaining respiratory specimen were available, co-infected microorganisms were
152 screened by FilmArray Respiratory Panel 2.1 (bioMérieux Japan, Tokyo, Japan), according
153 to manufacturer's instructions.

154

155 ***Generation of pseudotyped viruses***

156 Pseudotyped vesicular stomatitis virus (VSV) bearing SARS-CoV-2 S protein was
157 generated as previously described (1). The expression plasmid for the truncated S protein
158 of SARS-CoV-2, pCAG-SARS-CoV-2 S (Wuhan), were kindly provided from Dr. Shuetsu
159 Fukushi, National Institute of Infectious Diseases, Japan. The expression plasmids for the
160 truncated mutant S protein of SARS-CoV-2, pCAGG-pm3-SARS2-Shu-d19-B1.1.7
161 (UK-derived variant) and pCAGG-pm3-SARS2-Shu-d19-B1.351 (South Africa-derived
162 variant), were constructed by PCR-based site-directed mutagenesis using the cDNA as a
163 template, which obtained by chemical synthesis with optimization for the humanized codon
164 (Thermo Fisher Scientific, MA). The S cDNA of SARS-CoV-2 was cloned into the
165 pCAGGS-pm3 expression vector. Briefly, 293 T cells were transfected with above the
166 expression vectors. After 24 h of incubation, the transfected cells were infected with
167 G-complemented (*G) VSV Δ G/Luc (*G-VSV Δ G/Luc) at a multiplicity of infection of 0.5. The
168 virus was adsorbed and extensively washed four times with Dulbecco's modified Eagle's
169 medium (DMEM) supplemented with 10% fetal bovine serum (FBS). After 24 h of incubation,
170 the culture supernatants containing pseudotyped VSVs were centrifuged to remove cell
171 debris and stored at -80 °C until further use.

172

173

174 ***Serological tests***

175 The neutralizing effects of samples against pseudotyped viruses were examined in
176 96-well microplates (Thermo Fisher Scientific, MA) by the CRNT, as previously described
177 (1). In this study, we utilized VeroE6/TMPRSS2 cells, which were highly susceptible for
178 SARS-CoV-2 infection. VeroE6/TMPRSS2 cells (JCRB1819) was purchased from
179 Japanese Collection of Research Bioresources (JCRB) Cell Bank (Osaka, Japan). Briefly,
180 serum-containing DMEM (Nacalai Tesque, Inc., Kyoto, Japan) with 10% heat-inactivated
181 FBS was incubated with pseudotyped SARS-CoV-2 for 1 h. After incubation, Vero E6
182 TMPRSS2 cells were treated with DMEM-containing serum and pseudotyped virus. The
183 infectivity of the pseudotyped viruses was determined by measuring the luciferase activity
184 after 24 h of incubation at 37 °C. For the high-throughput assay (htCRNT), the CRNT was
185 modified, using 384-well microplates (Corning, NY).

186 For the commercial assay, the serum samples were tested at an external laboratory
187 company, using Elecsys Anti-SARS-CoV-2 S immunoassay (Roche Diagnostics GmbH,
188 Basel, Switzerland) to quantitatively measure the antibody levels to the SARS-CoV-2 RBD.
189 The manufacturer's cut-off value (COV) was 0.8 U/mL and the minimum value was
190 expressed as <0.4 U/mL.

191

192 ***Statistical analysis***

193 Statistical analysis was performed using the Kruskal-Wallis test with Dunn's test for
194 multiple comparisons among three groups or more. Correlations between test findings were
195 expressed using Pearson's correlation coefficients. Positive conversion was analyzed by
196 the Kaplan-Meier method, using the Gehan-Breslow-Wilcoxon test. Data were analyzed,
197 using GraphPad Prism version 8.4.3 (GraphPad Software, CA). Statistical significance
198 between different groups is presented in the figure legend.

199

200 ***Ethics approval***

201 This study was performed in accordance with the Declaration of Helsinki and was
202 approved by the ethical review board of the University of Toyama (approval No.: R2019167
203 and R2020097). Written informed consent was obtained from all participants.

204

205

206 **Results**

207 To investigate the relationship between the clinical findings and seroconversion,
208 482 serum samples, excluding three samples with low volume remaining, were evaluated.
209 These samples were collected from confirmed COVID-19 patients (n = 74), confirmed
210 non-COVID-19 individuals (n = 179), and unscreened individuals (suspected healthy
211 individuals) (n = 229) (**Table 1**). Because in our previous study, moderate and severe

212 patients with COVID-19 showed > 50% inhibition (IC_{50}) in the CRNT after day 10 from
213 disease onset (2), the period after day 10 from disease onset was considered as the
214 convalescent phase. Neutralization activity against pseudotyped viruses and anti-RBD
215 antibody levels were evaluated by the CRNT (**Figure 1A**) and quantified by the
216 commercially available test (**Figure 1B**). Because asymptomatic individuals can have a
217 weak immune response to SARS-CoV-2 infection (16), the diagnostic performance of both
218 tests was evaluated by comparing the symptomatic confirmed COVID-19 patients in the
219 convalescent phase ($n = 24$) and the unscreened individuals (**Figure 1C**). Both tests clearly
220 classified these two groups (the best COVs, CRNT; 50.5, anti-RBD antibody test; 0.62).
221 Thus, in the following analysis, IC_{50} for the CRNT and 0.8 U/mL for the anti-RBD antibody
222 test (manufacturer's COV) were used as the COVs for predicting serological positive
223 conversion to SARS-CoV-2.

224 For the CRNT (**Figure 1A** and **Supplemental Table 1**), the percentage of positivity
225 in the symptomatic confirmed COVID-19 patients was 16.7% (7/42) in the acute phase and
226 95.8% (23/24) in the convalescent phase. The CRNT values of the symptomatic confirmed
227 COVID-19 patients (median 83.5; IQR 64.1-90.0) were significantly higher than those of the
228 unscreened individuals (% positivity: 0.9% [2/229], median 17.0; IQR 0.0-31.2) ($p < 0.001$).
229 Conversely, symptomatic and asymptomatic confirmed non-COVID-19 individuals in the
230 convalescent phase showed significantly decreased CRNT values ($p < 0.001$).

231 For anti-RBD antibody levels (**Figure 1B** and **Supplemental Table 1**), in the
232 symptomatic confirmed COVID-19 patients, 14.3% (6/42) in the acute phase and 100.0%
233 (24/24) in the convalescent phase tested positive. In contrast, 0.0% (0/229) of the
234 unscreened individuals were positive. Compared with the unscreened group, symptomatic
235 confirmed COVID-19 patients in the acute phase, those in the convalescent phase, and
236 asymptomatic confirmed COVID-19 patients in the acute phase showed significant
237 increases in their serum anti-RBD antibody levels (median 0.40; IQR 0.40-0.40, median
238 0.40; IQR 0.40-0.46, median 35.0; IQR 7.63-137.0, and median 1.59; IQR 0.40-7.55,
239 respectively, $p < 0.001$).

240 Among the confirmed COVID-19 patients, the positivity of both tests was
241 time-dependent (**Figure 1D**). Positive conversion was observed 2 days after the onset or
242 the episode of close contact, and cases in the convalescent phase were positive for both
243 tests, excluding two cases sampled after 240 days. While the confirmed COVID-19 group
244 included sub-populations with RNAemia analyzed, it was independent of positive
245 conversion of the neutralization or anti-RBD antibody during the acute phase
246 (**Supplemental Figure 1**).

247

248 ***Relationship of the anti-RBD antibody test and neutralizing response***

249 To evaluate the indirect functional meaning of the anti-RBD antibody test, these
250 values were compared with those of the CRNT. The concordance of the CRNT and the
251 anti-RBD antibody test was 98.9% (477/482; double positive: n = 38; double negative: n =
252 439) (**Figure 2A**). Of five samples with discordance, four were slightly positive for CRNT
253 (53.5-69.0) but negative for anti-RBD antibody test (< 0.40 U/mL). For the other
254 discordance, of which the value of anti-RBD antibody test was slightly elevated (5.06 U/mL),
255 CRNT was partly inhibited (CRNT 35.5) but judged as negative. Discordance was not
256 related to the underlying diseases or medications.

257 Next, to evaluate whether the values measured by the anti-RBD antibody test
258 indirectly correlated with neutralizing activity, these values were compared with CRNT using
259 the diluted sera (**Figure 2B**). The values positively correlated with neutralizing titer ($r = 0.47$,
260 95% confidence interval 0.20-0.68); the sera with higher values tended to be positive for
261 CRNT (> 50% inhibition) despite being highly diluted.

262

263 ***Performance of high throughput assay***

264 To increase the number of simultaneous processing, the performance of htCRNT,
265 which is a high-throughput neutralizing assay on a 384-well plate, was also evaluated using
266 100-fold-diluted sera. The results of htCRNT correlated with those of CRNT ($r = 0.83$, 95%
267 confidence interval 0.80-0.86), and concordance was 98.8% (476/482). Six discordant

268 samples were negative for htCRNT but positive for CRNT (**Supplemental Figure 2A** and
269 **Supplemental Table 2**). Significant inhibition was observed in symptomatic confirmed
270 COVID-19 in the convalescent phase (median 83.5; IQR 67.7-91.0) compared to the
271 unscreened individuals (median 0.0; IQR 0.0-11.0, $p < 0.001$, **Supplemental Figure 2B**).
272 The cut-off value was set as IC_{50} based on the ROC analysis (**Supplemental Figure 2C**),
273 and the concordance of the two tests was 99.4% (479/482; double positive: $n = 36$; double
274 negative: $n = 443$, **Supplemental Figure 2D**). Three discordant samples were positive for
275 the anti-RBD antibody test but negative for the htCRNT (htCRNT 28-41). Three cases in the
276 convalescent phase were negative for the htCRNT (**Supplemental Figure 2E**).

277

278 ***Evaluation of cross reaction to pseudotyped SARS-CoV-2 variants***

279 Finally, to investigate the neutralizing activity against SARS-CoV-2 variants,
280 CRNT-positive samples were assayed using pseudotyped SA and UK-derived variants.
281 Compared to the wild-type pseudotyped virus (Wuhan), the CRNT values against the UK
282 and SA-derived variants were significantly decreased (median 80.8; IQR 66.4-88.8 for WT,
283 vs. median 53.4; IQR 36.7-67.4; median 43.1; IQR 14.2-60.2, respectively) (**Figure 3A**).
284 The percentages of serum samples above CRNT 50.0 were 77.8% (7/9) for UK-derived
285 variant and 88.9% (8/9) for SA-derived variant among samples with ≥ 100 U/mL by
286 anti-RBD antibody test, while those were 53.6% (15/28) for UK-derived variant and 32.1%

287 (9/28) for SA-derived variant among samples with 0.8-<100 U/mL by the anti-RBD antibody
288 test (**Figure 3B**).

289

290 **Discussion**

291

292 The commercial antibody test used in the present study showed excellent
293 correlation with the CRNT, suggesting that it is helpful to speculate on the protective
294 antibody response. Because it can detect antibodies specific to the RBD, the values may
295 reflect the number of antibodies with protective functions against SARS-CoV-2 (17, 18).
296 Similarly, assays detecting antibodies against the RBD protein have shown better
297 correlation with neutralizing activity than those against the N protein (4); however, the
298 correlation depends on the manufacturer (3, 4). Our findings suggest that CRNT and
299 anti-RBD antibody tests are suitable for detecting SARS-CoV-2 infection. Seropositive
300 individuals in the non-COVID-19 and unscreened groups might acquire an immune
301 response without noticing SARS-CoV-2 infection or cross-react with other antigens.
302 However, the serological response against SARS-CoV-2 is not yet fully understood.
303 Cross-reactivity against SARS-CoV-2 spike protein may exist (19, 20) whereas normal
304 intravenous immunoglobulin collected before the COVID-19 pandemic has no direct effect
305 against SARS-CoV-2 (21).

306 Meanwhile, it remains unclear what value may indicate reasonable protection from
307 the future risk of SARS-CoV-2 exposure. It is important to know whether seropositivity can
308 protect against secondary exposure to SARS-CoV-2 (22). To confirm this effect, longitudinal
309 observations are required. However, the values of the anti-RBD antibody test and CRNT
310 showed a positive correlation, which is consistent with previous reports (3, 23). While not all
311 antibodies against the RBD are neutralizing (24), the quantitative value of the anti-RBD
312 antibody test may partly reflect the prophylactic function.

313 The long-term sustainability of effective immunity after recovery from COVID-19
314 remains controversial. While early reports indicated sustained humoral immunity in the sera
315 from previously infected patients (18, 25), SARS-CoV-2 reinfection has been reported
316 despite the development of humoral immune response after primary infection (26, 27).
317 Although neutralizing antibodies may disappear after 6 months or longer after the onset (4),
318 in the present study, most of the convalescent sera from COVID-19 patients showed
319 inhibition of viral infection. Asymptomatic COVID-19 patients may have a weaker immune
320 response than symptomatic patients or show a relative reduction in anti-RBD antibody and
321 neutralizing antibody levels, as previously reported (16). These findings support the
322 evidence of long-term immunity against SARS-CoV-2, in particular, in symptomatic patients;
323 however, continuous precautions, including infection control and prevention and vaccination

324 are required for reliable immunity, as convalescent sera can contain insufficient levels of
325 neutralizing activity (25).

326 Cross-reactivity to SARS-CoV-2 variants was clinical interest. In the present study,
327 the reduction in neutralization was observed for the SA and UK-derived variants compared
328 with the wild-type. In previous reports, neutralization against the UK variant including
329 UK-derived variant were similar when compared with those to the wild-type (11, 28, 29). In
330 contrast, the reduction in neutralization against the UK variant has been also observed in
331 previous reports (13, 14, 29). Our findings suggest that the neutralization against UK variant
332 cannot be completely similar to wild-type, supporting the systematic report (29). For the
333 SA-derived variant, neutralization was significantly reduced as previously reported (11, 28,
334 29). However, most of sera reacted at least slightly to the SA pseudotyped virus even
335 though the CRNT values were smaller than those associated with the wild-type
336 pseudotyped virus, suggesting that they had a partial cross-reaction. In addition,
337 cross-reactivity was partly reflected in the values obtained with the commercial anti-RBD
338 antibody test. These findings imply that the total amount of antibodies against SARS-CoV-2
339 RBD can serve as an indirect indicator of a protective role against these variants.

340 The microassay, htCRNT, showed a good correlation with the CRNT. Because it
341 requires a smaller volume of serum and virus solution than the standard CRNT, a large
342 number of samples can be simultaneously assayed in a plate. Furthermore, because the

343 neutralizing antibody test is the gold standard for assessing functional immune status
344 against the virus, it can provide evidence for planning the recovery of social activity. There
345 are many issues regarding immune status, such as the antibody response of healthcare
346 workers after vaccination, and the antibody retention ratio in the community. Therefore, a
347 high-throughput option can provide an opportunity to conduct large-scale screening.

348 There are several limitations to the present study. First, serum samples in the
349 present study were one-time collections. Therefore, the continuous antibody level trend and
350 its relationship with disease severity could not be evaluated. Second, sera from individuals
351 who had no evidence of infection, such as sera before the COVID-19 pandemic, could not
352 be set as a control. Lastly, it is unknown whether cross-reactivity to variants is also
353 observed in other commercial antibody tests. Because antigen-antibody relationships are
354 specific, the test performance should be evaluated individually.

355 The CRNT and anti-RBD antibody tests efficiently detect convalescent COVID-19
356 patients. Because most facilities cannot evaluate neutralizing antibodies, the good
357 correlation of the non-functional antibody test with the CRNT may help assess the levels of
358 functional antibodies in COVID-19 patients and vaccinated individuals.

359

360 **Transparency declaration**

361 **Conflicts of interest**

362 The authors have no conflicts of interest to declare.

363

364 **Funding**

365 This study was supported by the Research Program on Emerging and Re-emerging

366 Infectious Diseases from AMED Grant No. JP20he0622035.

367

368 **Acknowledgments**

369 We thank all the staff at Toyama University Hospital and Toyama City Hospital for

370 their help in collecting specimens. We also thank Yumiko Nakagawa and Yoriko Ito for their

371 secretarial assistance. We would like to thank Mayu Somekawa for the arrangement of the

372 specimens.

373 **Contribution**

374 Conceptualization YoMo

375 Methodology YoMo, HT

376 Validation YoMo, HT

377 Formal Analysis YoMo

378 Investigation YoMo, HT, HK, TS, EI, YS, MK, and YuMu (neutralizing assay)

379 YoYo, RY (viral investigations)
380 Resources HT, TS, EI, YS (generating pseudotyped viruses)
381 CO, YoMa (generating plasmids)
382 YT, SN, HK, MK, YuMu, AU, YuMi, YF, and KN (collecting serum
383 samples)
384 Data Curation YoMo, HT
385 Writing – Original Draft Preparation YoMo, HT
386 Writing – Review and Editing YoMo, HT, YU, AS, YK
387 Visualization YoMo
388 Supervision TF, YI, KO, YoYa
389 Project Administration YoMo, YoYa
390 Funding YoMo, HT, YoYa

391

392 References

393

- 394 1. Tani H, Kimura M, Tan L, Yoshida Y, Ozawa T, Kishi H, Fukushi S, et al. Evaluation of
395 SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing
396 SARS-CoV-2 spike protein. *Virology* 2021;18:16.
- 397 2. Kawasuji H, Morinaga Y, Tani H, Kimura M, Yamada H, Yoshida Y, Takegoshi Y, et al.
398 Dynamics of neutralizing antibody responses in acute-phase COVID-19: A potential
399 relationship between disease progression and rapid neutralizing antibody response.
400 medRxiv. 2021. doi: <https://doi.org/10.1101/2021.02.06.21251246>
- 401 3. Rubio-Acero R, Castelletti N, Fingerle V, Olbrich L, Bakuli A, Wölfel R, Girel P, et al. In

- 402 search for the SARS-CoV-2 protection correlate: A head-to-head comparison of two
403 quantitative S1 assays in a group of pre-characterized oligo-/asymptomatic patients.
404 medRxiv. 2021. doi: <https://doi.org/10.1101/2021.02.19.21252080>
- 405 4. Bal A, Trabaud MA, Fassier JB, Rabilloud M, Saker K, Langlois-Jacques C, Guibert
406 N, et al. Six-month antibody response to SARS-CoV-2 in healthcare workers
407 assessed by virus neutralization and commercial assays. *Clin Microbiol Infect.* 2021.
408 doi: 10.1016/j.cmi.2021.01.003.
- 409 5. Herroelen PH, Martens GA, De Smet D, Swaerts K, Decavele A-S. Humoral Immune
410 Response to SARS-CoV-2: Comparative Clinical Performance of Seven Commercial
411 Serology Tests. *Am J Clin Pathol* 2020;154:610-9
- 412 6. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh
413 D, et al. Emergence of a SARS-CoV-2 variant of concern with mutations in spike
414 glycoprotein. *Nature* 2021:1-8.
- 415 7. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh
416 D, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature*
417 2021;592:438-43.
- 418 8. Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H, Leng Y, Robinson ML, et al. Viral
419 epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of
420 severity. *Science* 2020;370 6520.
- 421 9. Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, Conner T, et al.
422 Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK
423 defined by a novel set of spike mutations.
424 [https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-co](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-co-v-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)
425 [v-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-co-v-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563) (Accessed May
426 1 2021).
- 427 10. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KH, Dingens AS, Navarro MJ, et
428 al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals
429 constraints on folding and ACE2 binding. *Cell* 2020;182:1295-310.
- 430 11. Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Boehm-Cohen L, Raviv Y,
431 Shemer-Avni Y, et al. SARS-CoV-2 spike variants exhibit differential infectivity and
432 neutralization resistance to convalescent or post-vaccination sera. *Cell Host Microbe*
433 2021;29:522-8.
- 434 12. Haynes WA, Kamath K, Lucas C, Shon J, Iwasaki A. Impact of B. 1.1. 7 variant
435 mutations on antibody recognition of linear SARS-CoV-2 epitopes. medRxiv 2021.
436 doi: <https://doi.org/10.1101/2021.01.06.20248960>
- 437 13. Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, Zhao Y, et al.
438 Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and
439 vaccine sera. *Cell* 2021;184:2201-2211.e7.

- 440 14. Bates TA, Leier HC, Lyski ZL, McBride SK, Coulter FJ, Weinstein JB, Goodman JR,
441 et al. Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum.
442 medRxiv. 2021 doi: 10.1101/2021.04.04.21254881.
- 443 15. Kawasuji H, Morinaga Y, Tani H, Yoshida Y, Takegoshi Y, Kaneda M, Murai Y, et al.
444 SARS-CoV-2 RNAemia with higher nasopharyngeal viral load is strongly associated
445 with severity and mortality in patients with COVID-19. medRxiv. 2020. doi:
446 <https://doi.org/10.1101/2020.12.17.20248388>
- 447 16. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, et al. Clinical and
448 immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*
449 2020;26:1200-4.
- 450 17. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M,
451 Jiang K, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans.
452 *Nat Med* 2020;26:1033-6.
- 453 18. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, et al.
454 Persistence and decay of human antibody responses to the receptor binding domain
455 of SARS-CoV-2 spike protein in COVID-19 patients. *Science Immunol* 2020;5 52.
- 456 19. Tso FY, Lidenge SJ, Peña PB, Clegg AA, Ngowi JR, Mwaiselage J, Ngalamika O, et
457 al. High prevalence of pre-existing serological cross-reactivity against severe acute
458 respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. *Int J*
459 *Infect Dis.* 2021;102:577-83.
- 460 20. Li D, Li J. Immunologic Testing for SARS-CoV-2 Infection from the Antigen
461 Perspective. *J Clin Microbiol* 2021;59 5.
- 462 21. Kubota - Koketsu R, Terada Y, Yunoki M, Sasaki T, Nakayama EE, Kamitani W,
463 Shioda T. Neutralizing and binding activities against SARS - CoV - 1/2, MERS - CoV,
464 and human coronaviruses 229E and OC43 by normal human intravenous
465 immunoglobulin derived from healthy donors in Japan. *Transfusion* 2021;61:356-60.
- 466 22. Bartsch YC, Fischinger S, Siddiqui SM, Chen Z, Yu J, Gebre M, Atyeo C, et al.
467 Discrete SARS-CoV-2 antibody titers track with functional humoral stability. *Nature*
468 *Communications* 2021;12:1018.
- 469 23. Rus KR, Korva M, Knap N, Županc TA, Poljak M. Performance of the rapid
470 high-throughput automated electrochemiluminescence immunoassay targeting total
471 antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison
472 to the neutralization assay. *J Clinl Virol* 2021:104820.
- 473 24. Yuan M, Liu H, Wu NC, Lee CD, Zhu X, Zhao F, Huang D, et al. Structural basis of a
474 shared antibody response to SARS-CoV-2. *Science* 2020;369:1119-23.
- 475 25. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, et al.
476 Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*
477 2020;584:437-42.

- 478 26. Selhorst P, Van Ierssel S, Michiels J, Mariën J, Bartholomeeusen K, Dirinck E,
479 Vandamme S, et al. Symptomatic SARS-CoV-2 reinfection of a health care worker in
480 a Belgian nosocomial outbreak despite primary neutralizing antibody response. *Clin*
481 *Infect Dis*. 2020. in press. doi: 10.1093/cid/ciaa1850.
- 482 27. Adrielle Dos Santos L, Filho PGG, Silva AMF, Santos JVG, Santos DS, Aquino MM,
483 de Jesus RM, et al. Recurrent COVID-19 including evidence of reinfection and
484 enhanced severity in thirty Brazilian healthcare workers. *J Infection*
485 2021;82:399-406.
- 486 28. Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C,
487 et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to
488 neutralizing antibodies. *Nat Med* 2021 in press. doi: 10.1038/s41591-021-01318-5.
- 489 29. Chen X, Chen Z, Azman AS, Sun R, Lu W, Zheng N, Zhou J, et al. Comprehensive
490 mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural
491 infection or vaccination. medRxiv doi: 10.1101/2021.05.03.21256506.
- 492
- 493

494 **Tables**

495 **Table 1. Demographic and clinical characteristics of the study participants**

496

Profile	Confirmed COVID-19, n=74	Confirmed non-COVID-19, n=179	Unscreened, n=229
Sex, male, n (%)	32 (43.2)	60 (33.5)	101 (44.1)
Age, years, n (%)			
≤19	4 (5.4)	1 (0.6)	0 (0.0)
20-29	14 (18.9)	42 (23.5)	51 (22.3)
30-39	11 (14.9)	51 (28.5)	71 (31.0)
40-49	6 (8.1)	39 (21.8)	53 (23.1)
50-59	10 (13.5)	25 (14.0)	35 (15.3)
60-69	9 (12.2)	11 (6.1)	19 (8.3)
≥70	20 (27.0)	10 (5.6)	0 (0.0)
Symptom, n (%)			
Symptomatic	66 (89.2)	56 (31.3)	NA
Fever	50 (67.6)	22 (12.3)	
Cough	43 (58.1)	22 (12.3)	
Sputum	18 (24.3)	17 (9.5)	
Sore throat	15 (20.3)	19 (10.6)	
Nasal discharge	7 (9.5)	13 (7.3)	
Loss of taste	22 (29.7)	2 (1.1)	
Loss of smell	25 (33.8)	3 (1.7)	
Dyspnea	21 (28.4)	11 (6.1)	
Others	19 (25.7)	12 (6.7)	
Asymptomatic	8 (10.8)	123 (68.7)	NA
Phase of blood sampling, n (%)			
Acute (< 9 days from onset or a close contact episode), n (%)	48 (64.9)	5 (2.8)	NA
Convalescent (≥10 days from onset or a close contact episode), n (%)	26 (35.1)	174 (97.2)	NA
Underlying diseases, n (%)			
Yes	14 (18.9)	10 (5.6)	NA

Malignant diseases	2 (2.7)	4 (2.2)	
Diabetes	8 (10.8)	7 (3.9)	
Immunosuppression	3 (4.1)	1 (0.6)	
Renal failure	5 (6.8)	2 (1.1)	
Liver failure	0 (0.0)	1 (0.6)	
Systemic lupus erythematosus	0 (0.0)	0 (0.0)	
No	60 (81.1)	169 (94.4)	NA
Medication, n (%)			
Yes	5 (6.8)	7 (3.9)	NA
Corticosteroids (excluding ointment)	3 (4.1)	6 (3.3)	
Immunosuppressants	1 (1.4)	1 (0.6)	
Anti-tumor drugs	0 (0.0)	0 (0.0)	
Anti-rheumatoid drugs	1 (1.4)	1 (0.6)	
Radiological therapy	0 (0.0)	1 (0.6)	
No	69 (93.2)	172 (96.1)	NA

497 NA, not applicable

498

Supplementary Table 1. Basic statistics of SARS-COV-2 serological tests

Profile	Confirmed COVID-19				Confirmed non-COVID-19				Unscreened	
	symptomatic		asymptomatic		symptomatic		asymptomatic			
	acute	convalescent	acute	convalescent	Acute	convalescent	acute	convalescent		
N	42	24	6	2	3	53	2	121	229	
CRNT (%)										
Minimum	0.0	35.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
25% Percentile	0.0	64.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Median	0.0	83.5	34.5	34.7	0.0	0.0	22.5	0.0	0.0	17.0
75% Percentile	30.6	90.0	75.2	69.5	0.0	17.5	45.0	21.2	0.0	31.2
Maximum	95.5	98.5	86.5	69.5	0.0	91.0	45.0	92.0	0.0	19.0
htCRNT (%)										
Minimum	0.0	28.0	0.0	10.0	0.0	0.0	0.0	0.0	0.0	0.0
25% Percentile	0.0	67.2	0.0	10.0	0.0	0.0	0.0	0.0	0.0	0.0
Median	0.0	83.5	45.5	25.5	0.0	0.0	2.0	0.0	0.0	0.0
75% Percentile	15.0	91.0	86.0	31.0	0.0	0.0	4.0	0.0	0.0	11.0
Maximum	98.0	98.0	89.0	31.0	0.0	83.0	4.0	91.0	0.0	50.0
Anti-RBD antibody (U/mL)										
Minimum	0.40	0.84	0.40	0.40	0.40	0.40	0.40	0.40	0.40	0.40
25% Percentile	0.40	7.63	0.40	0.40	0.40	0.40	0.40	0.40	0.40	0.40
Median	0.40	35.0	1.59	16.4	0.40	0.40	0.40	0.40	0.40	0.40
75% Percentile	0.46	137.0	7.55	32.4	0.40	0.40	0.40	0.40	0.40	0.40
Maximum	25.1	1640	12.3	32.4	0.40	66.4	0.40	294.0	0.40	0.40

500 CRNT; chemiluminescent reduction neutralizing test, htCRNT; high-throughput CRNT, RBD; receptor binding domain

501 **Figure 1 Neutralization and anti-RBD antibody levels**

502 **(A)** Neutralization levels against pseudotyped viruses measured by CRNT (serum
503 dilution, x 100). **(B)** Anti-RBD antibody levels measured by commercially available test. **(C)**
504 ROC curves to classify the symptomatic confirmed COVID-19 patients in the convalescent
505 phase and the unscreened individuals. **(D)** Relationship between results of each test and
506 time from symptom onset or a close contact episode to blood sampling in COVID-19
507 patients. Symptomatic and asymptomatic individuals are presented in red and blue (blue
508 arrowhead for overlapping cases), respectively.

509 *** indicates $p < 0.001$ by unpaired Kruskal-Wallis test and Dunn's multiple
510 comparison with setting the unscreened group as a control. Ac, acute phase; Co,
511 convalescent phase; S, symptomatic; AS, asymptomatic; Unscr., unscreened; AUC, area
512 under the curve; COV, cut-off value; Sn, sensitivity; Sp, specificity.

513

514 **Figure 2 Relationship between CRNT and anti-RBD antibody test**

515 **(A)** Comparison of neutralization levels and anti-RBD antibody results. Concordant
516 samples are red (positive for both tests) or white (negative for both tests). Discordant
517 samples are green (positive for anti-S antibody) or yellow (positive for CRNT). Dotted line of
518 CRNT indicates 50% of infectivity (IC_{50}). **(B)** Values of anti-RBD antibody test and
519 neutralizing activity. Sera positive for CRNT (serum dilution, x100) were serially diluted up

520 to x6400 and the dilution with $>IC_{50}$ was defined as a neutralizing titer. Box indicate median
521 and interquartile. Error bars indicate minimum to maximum.

522

523 **Figure 3 Neutralizing activities against SARS-CoV-2 variants in**
524 **Wuhan-CRNT-positive sera**

525 **(A)** Neutralizing sensitivity of SARS-CoV-2 pseudotyped variants. Neutralization of
526 wild-type (WT) spike protein (Wuhan) CRNT-positive sera (serum dilution, x100) was
527 assessed, using pseudotyped viruses displaying the mutant spike proteins (UK and
528 SA-derived variants). Box indicate median and interquartile. Error bars indicate minimum to
529 maximum. **(B)** Relationship between values of anti-RBD-antibody test and neutralization
530 against UK and SA-derived variants (serum dilution, x100).

531

532 **Supplemental Figure 1**

533 Relationship between seroconversion and RNAemia in confirmed COVID-19
534 patients in the acute phase. The Kaplan-Meier analysis was performed only for patients
535 who had RNAemia. ns; not significant.

536

537 **Supplemental Figure 2**

538 **(A)** Correlation between htCRNT and CRNT. Neutralization was assessed using
539 x100-diluted serum samples. Correlations were expressed using Pearson's correlation
540 coefficients. **(B)** Neutralization levels against pseudotyped viruses measured, using
541 htCRNT. **(C)** ROC curve of htCRNT for classification of symptomatic confirmed COVID-19
542 patients in the convalescent phase and unscreened individuals. **(D)** Comparison of htCRNT
543 neutralization levels and anti-S antibody results. Concordant samples were red (positive for
544 both tests) or white (negative for both tests). Discordant samples were green (positive for
545 anti-S antibodies). The dotted line of htCRNT indicates 50% inhibition (IC_{50}). **(E)**
546 Relationship between the results of htCRNT and time from symptom onset or a close
547 contact episode to blood sampling in COVID-19 patients. Symptomatic and asymptomatic
548 individuals are presented in red and blue (blue arrowhead for overlapped), respectively.

549 Error bars indicate medians (middle lines) and interquartile range. *** indicates $p <$
550 0.001 by unpaired Kruskal-Wallis test and Dunn's multiple comparison (unscreened group
551 as a control). Ac, acute phase; Co, convalescent phase; S, symptomatic; AS,
552 asymptomatic; Unscr., unscreened; AUC, area under the curve; COV, cut-off value; Sn,
553 sensitivity; Sp, specificity.

Fig. 1




Fig. 2






Fig. 3



Supplemental Fig. 1



Supplemental Fig. 2

